Panacos Pharmaceuticals IncOver The Counter Market:PANC
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Panacos Pharmaceuticals Inc | 50.0 | 0.0x | --- |
RightSmile Inc | 30.0K | 0.0x | --- |
Entia Biosciences Inc | 3.4K | 0.0x | --- |
RegeneRx Biopharmaceuticals Inc | 2.1K | 0.0x | --- |
US Stem Cell Inc | 640.0 | 0.0x | --- |
Trex Wind-Down Inc | 340.0 | 0.0x | --- |
Company Information
Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.
Contact Information
- Headquarters
- 134 Coolidge AveWATERTOWN, MA, United States 02472-2815
- Phone
- 617-926-1551
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jeremy Hayward-Surry
- President, Chief Executive Officer, Director
- Alan Dunton
- Senior Vice President - Drug Development
- David Martin
- Vice President - Finance, Principal Accounting Officer
- Robert Pelletier
- Vice President - Regulatory Affairs
- Tom Lategan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $50.00 |
|---|---|
Revenue (TTM) | $99.0K |
Shares Outstanding | 53.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.67 |
Book Value | $0.54 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -34,568.69% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
